<p>Immunic, Inc.（纳斯达克代码：IMUX - 获取免费报告）在目前覆盖该股票的九家券商中被赋予了 “买入” 的共识推荐，Marketbeat Ratings 报告称。七位研究分析师对该股票给予了买入推荐，另外两位则给予了强烈买入推荐。在过去一年中，发布报告的分析师对该股票的平均一年目标价格为 12.67 美元。</p>
<p>IMUX 已成为几份研究报告的主题。HC Wainwright 在 2 月 21 日的研究报告中重申了 “买入” 评级，并对 Immunic 的股票设定了 10.00 美元的目标价格。William Blair 在周二对 Immunic 的股票进行了覆盖，并对该股票设定了 “跑赢大盘” 的评级。D. Boral Capital 在 2 月 26 日的研究报告中重新发布了 “买入” 评级，并对 Immunic 的股票设定了 17.00 美元的目标价格。最后，StockNews.com 在 3 月 20 日的研究报告中将 Immunic 的股票评级从 “持有” 下调至 “卖出”。</p>
<p><strong>查看我们对 Immunic 的最新分析</strong></p>
<h2>Immunic 股票上涨 3.3%</h2>
<p>Immunic 股票在周五开盘价为 1.24 美元。该公司的市值为 1.117 亿美金，市盈率为-1.01，贝塔值为 1.89。Immunic 的 12 个月最低价为 0.92 美元，最高价为 2.11 美元。该公司的 50 日移动平均价格为 1.08 美元，200 日移动平均价格为 1.21 美元。</p>
<h2>对 Immunic 的对冲基金看法</h2>
<p>一些对冲基金最近调整了对 IMUX 的持股。Jane Street Group LLC 在第三季度将其在 Immunic 的股份增加了 121.4%。Jane Street Group LLC 现在拥有 70,299 股该公司的股票，价值 116,000 美元，此前在上个季度购买了 38,553 股。HB Wealth Management LLC 在第四季度购买了 Immunic 的新股份，价值约 81,000 美元。State Street Corp 在第三季度将其在 Immunic 的持股增加了 7.5%。State Street Corp 现在拥有 167,145 股该公司的股票，价值 276,000 美元，此前在上个季度购买了 11,642 股。Connor Clark &amp; Lunn Investment Management Ltd. 在第三季度将其在 Immunic 的持股增加了 70.8%。Connor Clark &amp; Lunn Investment Management Ltd. 现在拥有 102,257 股该公司的股票，价值 169,000 美元，此前在上个季度购买了 42,383 股。最后，Virtu Financial LLC 在第三季度购买了 Immunic 的新股份，价值约 50,000 美元。对冲基金和其他机构投资者持有该公司 51.82% 的股票。</p>
<h2>Immunic 公司简介</h2>
<p>（获取免费报告）</p>
<p>Immunic, Inc. 是一家生物技术公司，开发一系列选择性口服免疫疗法，用于治疗美国和德国的慢性炎症和自身免疫性疾病。其主要开发项目是 IMU-838，目前正在进行第三阶段临床试验，旨在治疗多发性硬化症，包括复发性和进展性多发性硬化症；以及中度至重度溃疡性结肠炎。</p>
<h2>进一步阅读</h2>
<ul>
<li>五只我们更看好的股票，而不是 Immunic</li>
<li>市盈率计算：如何评估股票</li>
<li>便士股票 SurgePays 上涨 70%：买入的一个理由，卖出的五个理由</li>
<li>股息捕捉策略：您需要知道的事项</li>
<li>三大饮料股票带来丰厚利润</li>
<li>ESG 股票，投资者应了解的事项</li>
<li>CarMax 和 Carvana：引领二手车市场</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU1VWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU1VWA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>您现在应该投资 1,000 美元于 Immunic 吗？</h2>
<p>在您考虑 Immunic 之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前立即购买……而 Immunic 并不在名单上。</p>
<p>虽然 Immunic 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

IMUX

<p>Immunic, Inc.（纳斯达克代码：IMUX）获得了九家券商的共识推荐评级为 “买入”，其中七位分析师给予 “买入” 评级，两位分析师给予 “强力买入” 评级。平均一年期目标价为 12.67 美元。最近的报告包括 HC Wainwright 的 10.00 美元目标价和 D. Boral Capital 的 17.00 美元目标价。Immunic 的股票开盘价为 1.24 美元，市值为 1.117 亿美金。对冲基金持有该公司 51.82% 的股份，该公司专注于开发慢性炎症和自身免疫疾病的治疗方案</p>

<p>Immunic, Inc. (NASDAQ:IMUX - Get Free Report) has been assigned a consensus recommendation of &#34;Buy&#34; from the nine brokerages that are currently covering the stock, Marketbeat Ratings reports. Seven research analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $12.67.</p>
<div class="lb-trans"><p>Immunic, Inc.（纳斯达克代码：IMUX - 获取免费报告）在目前覆盖该股票的九家券商中被赋予了 “买入” 的共识推荐，Marketbeat Ratings 报告称。七位研究分析师对该股票给予了买入推荐，另外两位则给予了强烈买入推荐。在过去一年中，发布报告的分析师对该股票的平均一年目标价格为 12.67 美元。</p>
</div><p>IMUX has been the subject of several research reports. HC Wainwright reaffirmed a &#34;buy&#34; rating and issued a $10.00 target price on shares of Immunic in a research note on Friday, February 21st. William Blair initiated coverage on shares of Immunic in a report on Tuesday. They set an &#34;outperform&#34; rating on the stock. D. Boral Capital reissued a &#34;buy&#34; rating and issued a $17.00 price target on shares of Immunic in a research note on Wednesday, February 26th. Finally, StockNews.com lowered shares of Immunic from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research report on Thursday, March 20th.</p>
<div class="lb-trans"><p>IMUX 已成为几份研究报告的主题。HC Wainwright 在 2 月 21 日的研究报告中重申了 “买入” 评级，并对 Immunic 的股票设定了 10.00 美元的目标价格。William Blair 在周二对 Immunic 的股票进行了覆盖，并对该股票设定了 “跑赢大盘” 的评级。D. Boral Capital 在 2 月 26 日的研究报告中重新发布了 “买入” 评级，并对 Immunic 的股票设定了 17.00 美元的目标价格。最后，StockNews.com 在 3 月 20 日的研究报告中将 Immunic 的股票评级从 “持有” 下调至 “卖出”。</p>
</div><p><strong>View Our Latest Analysis on Immunic</strong></p>
<div class="lb-trans"><p><strong>查看我们对 Immunic 的最新分析</strong></p>
</div><h2>Immunic Trading Up 3.3 %</h2>
<div class="lb-trans"><h2>Immunic 股票上涨 3.3%</h2>
</div><p>Shares of Immunic stock opened at $1.24 on Friday. The firm has a market capitalization of $111.70 million, a PE ratio of -1.01 and a beta of 1.89. Immunic has a 12 month low of $0.92 and a 12 month high of $2.11. The business's 50-day moving average price is $1.08 and its 200-day moving average price is $1.21.</p>
<div class="lb-trans"><p>Immunic 股票在周五开盘价为 1.24 美元。该公司的市值为 1.117 亿美金，市盈率为-1.01，贝塔值为 1.89。Immunic 的 12 个月最低价为 0.92 美元，最高价为 2.11 美元。该公司的 50 日移动平均价格为 1.08 美元，200 日移动平均价格为 1.21 美元。</p>
</div><h2>Hedge Funds Weigh In On Immunic</h2>
<div class="lb-trans"><h2>对 Immunic 的对冲基金看法</h2>
</div><p>A number of hedge funds have recently modified their holdings of IMUX. Jane Street Group LLC grew its stake in shares of Immunic by 121.4% in the third quarter. Jane Street Group LLC now owns 70,299 shares of the company's stock worth $116,000 after purchasing an additional 38,553 shares during the last quarter. HB Wealth Management LLC purchased a new stake in Immunic in the 4th quarter worth approximately $81,000. State Street Corp grew its position in shares of Immunic by 7.5% in the 3rd quarter. State Street Corp now owns 167,145 shares of the company's stock worth $276,000 after buying an additional 11,642 shares during the last quarter. Connor Clark &amp; Lunn Investment Management Ltd. grew its position in shares of Immunic by 70.8% in the 3rd quarter. Connor Clark &amp; Lunn Investment Management Ltd. now owns 102,257 shares of the company's stock worth $169,000 after buying an additional 42,383 shares during the last quarter. Finally, Virtu Financial LLC purchased a new position in shares of Immunic during the third quarter valued at approximately $50,000. Hedge funds and other institutional investors own 51.82% of the company's stock.</p>
<div class="lb-trans"><p>一些对冲基金最近调整了对 IMUX 的持股。Jane Street Group LLC 在第三季度将其在 Immunic 的股份增加了 121.4%。Jane Street Group LLC 现在拥有 70,299 股该公司的股票，价值 116,000 美元，此前在上个季度购买了 38,553 股。HB Wealth Management LLC 在第四季度购买了 Immunic 的新股份，价值约 81,000 美元。State Street Corp 在第三季度将其在 Immunic 的持股增加了 7.5%。State Street Corp 现在拥有 167,145 股该公司的股票，价值 276,000 美元，此前在上个季度购买了 11,642 股。Connor Clark &amp; Lunn Investment Management Ltd. 在第三季度将其在 Immunic 的持股增加了 70.8%。Connor Clark &amp; Lunn Investment Management Ltd. 现在拥有 102,257 股该公司的股票，价值 169,000 美元，此前在上个季度购买了 42,383 股。最后，Virtu Financial LLC 在第三季度购买了 Immunic 的新股份，价值约 50,000 美元。对冲基金和其他机构投资者持有该公司 51.82% 的股票。</p>
</div><h2>Immunic Company Profile</h2>
<div class="lb-trans"><h2>Immunic 公司简介</h2>
</div><p>(Get Free Report</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.</p>
<div class="lb-trans"><p>Immunic, Inc. 是一家生物技术公司，开发一系列选择性口服免疫疗法，用于治疗美国和德国的慢性炎症和自身免疫性疾病。其主要开发项目是 IMU-838，目前正在进行第三阶段临床试验，旨在治疗多发性硬化症，包括复发性和进展性多发性硬化症；以及中度至重度溃疡性结肠炎。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Immunic</li>
<li>P/E Ratio Calculation: How to Assess Stocks</li>
<li>Penny Stock SurgePays Rises 70%: 1 Reason to Buy, 5 to Sell</li>
<li>Dividend Capture Strategy: What You Need to Know</li>
<li>Top 3 Beverage Stocks Pouring Out Profits</li>
<li>ESG Stocks, What Investors Should Know</li>
<li>CarMax and Carvana: Steering the Used Car Market</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，而不是 Immunic</li>
<li>市盈率计算：如何评估股票</li>
<li>便士股票 SurgePays 上涨 70%：买入的一个理由，卖出的五个理由</li>
<li>股息捕捉策略：您需要知道的事项</li>
<li>三大饮料股票带来丰厚利润</li>
<li>ESG 股票，投资者应了解的事项</li>
<li>CarMax 和 Carvana：引领二手车市场</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU1VWA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=IMUX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Immunic Right Now?</h2>
<div class="lb-trans"><h2>您现在应该投资 1,000 美元于 Immunic 吗？</h2>
</div><p>Before you consider Immunic, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考虑 Immunic 之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunic wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前立即购买……而 Immunic 并不在名单上。</p>
</div><p>While Immunic currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Immunic 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Immunic, Inc. (NASDAQ:IMUX) 获得券商的平均评级为 “买入”